Search

• GSK receives positive CHMP opinion for Mekinist™ (trametinib) in metastatic melanoma with a BRAF V600 mutation

  Media

  (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on Mekinist™

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-mekinist-trametinib-in-metastatic-melanoma-with-a-braf-v600-mutation/

  First published: 25 April 2014

• motherapy for the treatment of relapsed or refractory diffuse large b-cell lymphoma

  Media

  GSK & GEN announced that the Phase III study ORCHARRD of Arzerra™ or rituximab plus chemotherapy for DLBCL did not meet its primary endpoint

  https://www.gsk.com/en-gb/media/press-releases/motherapy-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/

  First published: 19 May 2014

• Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology

  Media

  Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.

  https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/

  First published: 01 April 2014

• Results announcement for the fourth quarter 2012

  Media

  GSK delivers 2012 core EPS of 112.7p and returns £6.3bn to shareholders

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2012/

  First published: 06 February 2013

• Regulatory update: albiglutide US PDUFA date extended by three months

  Media

  GSK announced that PDUFA goal date for albiglutide, treatment for adult patients with type 2 diabetes, has been extended by three months.

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-albiglutide-us-pdufa-date-extended-by-three-months/

  First published: 02 August 2013

• Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children

  Media

  Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate.

  https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-reduces-disease-over-18-months-of-follow-up-in-late-stage-study-of-more-than-15-000-infants-and-young-children/

  First published: 08 October 2013

• GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors

  Media

  GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-jonathan-symonds-as-non-executive-chairman-of-the-board-of-directors/

  First published: 24 July 2019

• GSK receives CHMP positive opinion recommending approval of dostarlimab for women with recurrent or advanced endometrial cancer

  Media

  This positive CHMP opinion brings us closer to providing dostarlimab as a new treatment option to women with endometrial cancer in Europe

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-recommending-approval-of-dostarlimab-for-women-with-recurrent-or-advanced-endometrial-cancer/

  First published: 26 February 2021

• ‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme

  Media

  Cases of meningitis B halved after ten months

  https://www.gsk.com/en-gb/media/press-releases/real-world-data-shows-83-percent-effectiveness-for-bexsero-in-infants-in-first-year-of-uk-national-meningitis-b-immunisation-programme/

  First published: 05 September 2016

• FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over

  Media

  The data supports the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over.

  https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-votes-unanimously-for-shingrix-hzsu-in-the-us-for-prevention-of-herpes-zoster-shingles-in-adults-ages-50-and-over/

  First published: 13 September 2017